1. Scrip
  2. >>Business

Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies

Conjugation Tech Could Improve Gene Delivery

 
• By Andrew McConaghie

The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.

Eye test in France
Rare genetic eye diseases have been among the first targets for pioneering gene therapies. • Source: Alamy

Paris, France-based biotech HORAMA is relaunching itself as Coave Therapeutics, and a €33.1m ($39m) series B fundraising to help accelerate its progress in the competitive world of gene therapy.

The company has been around since 2015, and its lead asset CTx-PDE6b, is currently in a Phase I/II trial for rare genetic eye diseases, called PDE6b inherited

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.